This is because voretigene neparvovec is specifically designed to address the RPE65 mutation, which is only present in 0.3% to 1% of the patients suffering from RP, and its effectiveness relies on the presence of this particular genetic variant. Here, RPE65 is linked to retinitis pigmentosa 1.